Germany Added 2.5 Million Women to Mammography Screening While Reopening Skin Cancer Screening After a Proposal to Suspend It
Germany is widening cancer screening where the evidence is settled and reopening it where cost is the question.
Oncology
Roche’s Hansoh ADC Deal Is Worth Over $15.5 Billion, With $400 Million Upfront for Programmes Still in the Lab
Roche is paying platform money for ADCs that do not exist yet, five times what it paid Hansoh for a clinical asset in 2025.
One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price
One price in Japan, response-linked payments in Australia, no public price in China: CAR-T sponsors face three markets.
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response
Denmark turned a January no on Tecartus into a yes by tying price to response, and renewed burosumab on a lower price.
Merck and Daiichi Pulled an ADC Filing as GSK Paid $110 Million for a KRAS Payload
Crowded topoisomerase I ADCs face a higher bar, while money moves to RAS payloads, bispecific ADCs and discovery tools.
Merck Has 26 Months to Move Keytruda Patients to a Shot Protected Until 2043
Merck’s Keytruda defence turns on one number: how many US patients are on the one-minute shot when biosimilars ship.
Jaypirca’s 80% Win Over Chemo Opens a First-Line CLL Fight With Three BTK Rivals
Jaypirca reaches first-line CLL on a win over chemo, and now has to take share from three covalent BTK inhibitors.
IQWiG Finds Two Conflicting Studies and No Billing Code Behind AI Lung Cancer Reading
In Germany, AI lung reading is a cost radiologists carry and payers never see, and IQWiG wants outcome trials.
Latvia Squeezes Access for 123,000 Patients Out of Price Deals as 124 Drugs Wait
Latvia is buying access with manufacturers’ money, inside a reimbursement budget NVD already expects to overrun.
Pharmac Will Fund Any Medicine for Young People With Paediatric-Origin Cancers, About 15 a Year
The numbers are small, but the rule is unusual: New Zealand funds by tumour type and protocol rather than product by product.